This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
R-Pharm
ClinicalTrials.gov Identifier:
NCT00568022
First received: December 3, 2007
Last updated: February 9, 2016
Last verified: February 2016
  Purpose
The purpose of this study is to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase II dose of ixabepilone in combination with capecitabine in Japanese participants with metastatic breast cancer.

Condition Intervention Phase
Breast Cancer Drug: Ixabepilone Drug: Capecitabine Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Resource links provided by NLM:


Further study details as provided by R-Pharm:

Primary Outcome Measures:
  • Participants Experiencing Dose Limiting Toxicity (DLT) [ Time Frame: From initiation of drug through last day of Cycle 2 (Day 42) ]
    DLT was defined as any ixabepilone and/or capecitabine related events requiring study discontinuation during the first two treatment cycles.

  • Participants Achieving the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) [ Time Frame: At the end of Cycle 2 (Day 42) ]
    The MTD was defined as the highest dose evaluated for which less than 1/3 of the participants experienced DLT during the first two treatment cycles. If toxicities (e.g. hand-foot syndrome, existing peripheral neuropathy, etc.) occurred or became more severe in later cycles, the recommended Phase II dose was to be determined after due consideration of their severity.


Secondary Outcome Measures:
  • Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline to Day 42, continuously ]
    AE = any new untoward medical occurrence/worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE = any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related=Possible, Probable, or Certain relationship to drug

  • Participant Tumor Response at Study Endpoint [ Time Frame: At baseline and after every 42 days (every 2 21-day cycles) after baseline ]
    Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) in which complete response (CR) = disappearance of all target lesions; partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions; progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions; and stable disease (SD) = small changes that do not meet above criteria.

  • Mean Ixabepilone Maximum Plasma Concentration (Cmax) in One Dosing Interval [ Time Frame: During Cycle 1 at specified timepoints (Day 1 to Day 8). ]
    Cmax = maximum observed plasma concentration of ixabepilone as determined from participant serum samples in one dosing interval.

  • Mean Ixabepilone Area Under the Concentration Curve (AUC INF) in One Dosing Interval [ Time Frame: During Cycle 1 at specified timepoints (Day 1 to Day 8). ]
    AUC = the average area under the concentration curve (AUC [INF]) of ixabepilone as determined from participant serum samples in one dosing interval over 24 hours.

  • Mean Ixabepilone Terminal Elimination Half Life (T 1/2) in One Dosing Interval [ Time Frame: During Cycle 1 at specified timepoints (Day 1 to Day 8). ]
    T 1/2 = terminal elimination half life as determined from participant serum samples in one dosing interval.

  • Mean Ixabepilone Volume of Distribution at Steady State (Vss) in One Dosing Interval [ Time Frame: During Cycle 1 at specified timepoints (Day 1 to Day 8). ]
    Vss = volume of distribution at steady state determined from participant serum samples from one dosing interval.

  • Mean Ixabepilone Total Body Clearance (CLT) in One Dosing Interval [ Time Frame: During Cycle 1 at specified timepoints (Day 1 to Day 8). ]
    CLT = total body clearance as determined from participant serum samples in one dosing interval.


Enrollment: 9
Study Start Date: February 2008
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ixabepilone + Capecitabine Drug: Ixabepilone
Ixabepilone: Intravenous (IV) Solution, IV, 32(40)mg/m^2, once every 3 weeks, up to 6 cycles
Other Names:
  • IXEMPRA
  • BMS-247550
Drug: Capecitabine
Capecitabine: Tablets, Oral, 1650(2000)mg/m^2, twice daily for 2 weeks, one week off, up to 6 cycles

  Eligibility

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women ≥ 20 years
  • Histologically or cytologically confirmed diagnosis of adenocarcinoma originating in the breast

Exclusion Criteria:

  • Number of prior chemotherapy lines of treatment in the metastatic setting ≥3
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00568022

Locations
Japan
Local Institution
Matsuyama-Shi, Ehime, Japan, 7910280
Local Institution
Maebashi-Shi, Gunma, Japan, 371-8511
Local Institution
Sunto-Gun, Shizuoka, Japan, 411-8777
Local Institution
Osaka, Japan, 540-0006
Sponsors and Collaborators
R-Pharm
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Responsible Party: R-Pharm
ClinicalTrials.gov Identifier: NCT00568022     History of Changes
Other Study ID Numbers: CA163-117
Study First Received: December 3, 2007
Results First Received: June 3, 2011
Last Updated: February 9, 2016

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Capecitabine
Epothilones
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators

ClinicalTrials.gov processed this record on September 19, 2017